{
    "organizations": [],
    "uuid": "0f84b653d02e346fc97058f40d8ff4271e7d515b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-medivir-completes-directed-issue-o/brief-medivir-completes-directed-issue-of-around-155-mln-sek-idUSFWN1PS0E3",
    "ord_in_thread": 0,
    "title": "BRIEF-Medivir completes directed issue of around 155 mln SEK",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 2 (Reuters) - Medivir Ab:\n* MEDIVIR HAS COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY 155 MSEK\n* MEDIVIR SAYS ‍COMPANY INTENDS TO USE NET PROCEEDS FROM DIRECTED ISSUE TO MORE RAPIDLY ADVANCE DEVELOPMENT OF COMPANY‘S CLINICAL PORTFOLIO WHILE SIMULTANEOUSLY CONDUCTING OUT-LICENSING DISCUSSIONS FOR MIV-711, WITH AMBITION OF ENTERING INTO A PARTNER AGREEMENT DURING 2018​ Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)\n ",
    "published": "2018-02-02T15:12:00.000+02:00",
    "crawled": "2018-02-03T21:17:25.030+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "medivir",
        "ab",
        "medivir",
        "completed",
        "directed",
        "share",
        "issue",
        "approximately",
        "msek",
        "medivir",
        "say",
        "intends",
        "use",
        "net",
        "proceeds",
        "directed",
        "issue",
        "rapidly",
        "advance",
        "development",
        "company",
        "clinical",
        "portfolio",
        "simultaneously",
        "conducting",
        "discussion",
        "ambition",
        "entering",
        "partner",
        "agreement",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "stockholm",
        "newsroom"
    ]
}